Blogs | Multibagger Shares

May 17, 2026

Infographic the Klarman Doctrine Title with a Horizontal Bar Chart of Fy20fy25 Values Ending with a Green Fy25 Bar at 22

The Klarman Doctrine: Seth Klarman’s 1991 ‘Margin of Safety’ Three-Pillar Architecture — Why Absolute Returns, Bottom-Up Bargain Hunting, and Risk Aversion Define the Real Value Investor’s Edge

Seth Klarman's 1991 'Margin of Safety' rebuilt value investing on three pillars: absolute returns, bottom-up bargain hunting, and risk aversion. How Titan Biotech FY25's audited numbers illustrate all three.

May 16, 2026

Infographic style Hero Showing Four Investor Mindsets Lucky left Gray Confused left Light Gray Disciplined Investor right Green and Bias trapped right Orange

Myopic Loss Aversion (Benartzi & Thaler 1995): Why Indian Retail Investors Sabotage Long-Term Returns by Checking Portfolios Too Often

Myopic Loss Aversion — Benartzi & Thaler's 1995 Nobel-grade explanation of the equity premium puzzle, applied to Indian retail investors, with Titan Biotech FY25 audited numbers as an anti-MLA corporate-cadence case study.

May 16, 2026

Hero Header Net Debt to Ebitda Ratio with a Green Accent multibagger Shares and a Subtitle Line on a Dark Blue Background

Net Debt to EBITDA Ratio: The Single Solvency Test Credit Analysts Care About Most

Net Debt to EBITDA is the single ratio professional credit analysts use most when assessing survival odds. This educational deep-dive teaches how to read it, where retail investors misinterpret it, and how Titan Biotech (BSE: 524717) FY25 audited numbers illustrate a -0.75x net-cash fortress reading. Not a buy/sell recommendation.

May 16, 2026

Hero Section with Title look through Earnings over a Dark Blue Gradient Subtitle Text and a Centered Multicolor Donut Chart Labeled fy25 Reinvested

Look-Through Earnings: Warren Buffett’s 1990 Berkshire Letter Framework for Measuring Your True Portfolio Earnings

Warren Buffett's 1990 Berkshire letter introduced look-through earnings — dividends plus your proportional share of retained profits. Why this single number reveals what your portfolio truly earned, illustrated by Titan Biotech FY25's high-retention, low-debt capex discipline.